HBM HOLDINGS-B (02142.HK): Partner Solstice Oncology Closes USD 225 Million Series A Financing

NewTimeSpace News: On 9 September 2026, HBM Holdings Limited (stock code: 02142) issued a voluntary announcement stating that its partner company, Solstice Oncology, had completed a USD 225 million Series A financing and formally commenced operations. The round was led by RA Capital Management, with participation from Canaan Partners, Forbion and other investors.

According to the announcement, Solstice is a clinical-stage onco-immunology company focused on intervening in cancer earlier at the neoadjuvant stage. Founded in February 2026, Solstice is advancing its lead candidate, Pruluzubartamab, a second-generation Fc-enhanced antibody with differentiated properties targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The drug is currently being advanced in two clinical indications, one of which is microsatellite-stable (MSS) colon cancer and the other not yet disclosed; a Phase II study is evaluating pruluzubartamab in combination with pembrolizumab in the neoadjuvant treatment of MSS clinical stage II-III colon cancer. MSS is the most prevalent subtype of colon cancer, and this patient population has so far not benefited from immunotherapy. Patient enrolment in the Phase II trial is expected to begin in early Q4 2026, with study data expected in the second half of 2027.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.